8-K - Citius Pharmaceuticals, Inc. (0001506251) (Filer)
Published . Updated .
8-K - Citius Pharmaceuticals filed an 8-K with the SEC on Oct 26 (a notice of a material company event).
Directly affected
- CTXR Citius Pharmaceuticals-11.6% 5d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “pharmaceutical” (pharma and health) in this story.
- LLY Eli Lilly and+12.6% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- JNJ Johnson & Johnson+0.5% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- PFE Pfizer+8.4% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
- MRK Merck-2.1% 15d
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “pharmaceutical” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| CTXR | -0.23% | -14.09% | base | +20.02% | after close | after close | after close |
| XLVNo price data for this ticker | — | — | — | — | — | — | — |
| XBINo price data for this ticker | — | — | — | — | — | — | — |
| LLYNo price data for this ticker | — | — | — | — | — | — | — |
| JNJNo price data for this ticker | — | — | — | — | — | — | — |
| PFENo price data for this ticker | — | — | — | — | — | — | — |
| MRKNo price data for this ticker | — | — | — | — | — | — | — |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Filed: 2026-10-26 AccNo: 0001213900-26-112478 Size: 232 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Source: sec-edgar
Citius Pharmaceuticals (CTXR) since this story, compared with the market
| Company | When | Move | Status |
|---|---|---|---|
| Citius Pharmaceuticals (CTXR) | that day | +20.02% | final price |
| Citius Pharmaceuticals (CTXR) | three days earlier | -14.09% | final price |
| Citius Pharmaceuticals (CTXR) | five days earlier | -0.23% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 52 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 31 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 48 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 52 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 52 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 66 days before publication. Filed 8 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 31 Jul 2026. That is 87 days before publication. Filed 22 Sep 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 32 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 68 days before publication. Filed 9 Sep 2026. View the filing.
- Donald J Trump, an executive branch official, sold Merck (MRK), worth $250,001 - $500,000 on 31 Jul 2026. That is 87 days before publication. Filed 22 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who is named in “8-K - Citius Pharmaceuticals, Inc. (0001506251) (Filer)”
Companies carried with this story
- CTXR Citius Pharmaceuticals
In “8-K - Citius Pharmaceuticals, Inc. (0001506251) (Filer),” Citius Pharmaceuticals (CTXR) is linked, with no stored direction, high confidence. Reason on file: SEC 8-K filing -> direct issuer disclosure -> CTXR
How “8-K - Citius Pharmaceuticals, Inc. (0001506251) (Filer)” reaches Citius Pharmaceuticals (CTXR)
On 26 Oct 2026, “8-K - Citius Pharmaceuticals, Inc. (0001506251) (Filer)” is the story that connects Citius Pharmaceuticals (CTXR) to this story.
What ties Citius Pharmaceuticals (CTXR) to the headline is this: SEC 8-K filing -> direct issuer disclosure -> CTXR
Price levels for Citius Pharmaceuticals (CTXR)
CTXR traded between 0.43 and 0.52 across 2 sessions. The latest close on file is 0.52.
How solid “8-K - Citius Pharmaceuticals, Inc. (0001506251) (Filer)” looks
14 out of 100
“8-K - Citius Pharmaceuticals, Inc. (0001506251) (Filer)” scores 14 out of 100. The score uses 1 sources, and 1 linked companies.